PGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Precigen Inc (PGEN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong positive catalysts, including FDA approval and exclusivity for its flagship product PAPZIMEOS, which is driving robust sales growth. Despite hedge fund selling and insider sales, the long-term growth potential and bullish technical indicators make this stock a solid choice.
The stock is showing bullish momentum with MACD positively expanding and above 0, RSI at 74.926 in the neutral zone, and moving averages indicating an uptrend (SMA_5 > SMA_20 > SMA_200). The key resistance level is at 4.762, with support at 4.231. The stock is trading close to its resistance level, suggesting potential for further upside.
FDA approval and orphan drug exclusivity for PAPZIMEOS until
Strong Q1 sales performance exceeding guidance, with annualized sales of $86.4 million.
Analysts raising price targets to $14 and maintaining Buy/Outperform ratings.
SwingMax signal on 2026-06-11 with a 5.96% price increase since then.
Hedge funds have significantly increased selling activity (801.59% over the last quarter).
Insider selling by CFO, reducing ownership stake by 7%.
Financial data for the latest quarter is unavailable, but Q1 2026 sales exceeded $18 million, reflecting strong commercial execution and market demand for PAPZIMEOS.
Analysts are highly bullish on PGEN, with multiple firms raising price targets (e.g., H.C. Wainwright to $14, Citizens to $11) and maintaining Buy/Outperform ratings. Analysts cite strong sales performance, market exclusivity, and broad patient engagement as key drivers.
